Anti-counterfeiting measures for glass articles
A glass container including a body having a delamination factor less than or equal to 10 and at least one marking is described. The body has an inner surface, an outer surface, and a wall thickness extending between the outer surface and the inner surface. The marking is located within the wall thickness. In particular, the marking is a portion of the body having a refractive index that differs from a refractive index of an unmarked portion of the body. Methods of forming the marking within the body are also described.
1. A pharmaceutical package comprising:
a glass body having a delamination factor of less than or equal to 10, the glass body having an outer surface, the composition of the glass body at least partially phosphorescent under ultra-violet (UV) light;
a polymer-based coating disposed on at least a portion of the outer surface of the glass body;
an exposed portion of the outer surface of the glass body within a region of the polymer-based coating; and
a marking provided by the exposed portion of the outer surface of the glass body seen through the polymer-based coating that is visible to the naked eye; and
a covert marking, consisting of the phosphorescence of outer surface of the glass body exposed through the polymer-based coating that is only visible when the glass body is exposed to ultra-violet (UV) light.
2. The pharmaceutical package of claim 1 , wherein the polymer-based coating comprises a polyimide coating.
3. The pharmaceutical package of claim 1 , wherein the marking enables the pharmaceutical package to be traced through a manufacturing process, a filling process, or in a field of use.
4. The pharmaceutical package of claim 1 , wherein the glass body is formed from an alkali-aluminosilicate glass composition.
5. The pharmaceutical package of claim 1 , wherein the marking has a difference in UV absorption of greater than about 10% compared to a UV absorption of an unmarked portion of the pharmaceutical package.
6. The pharmaceutical package of claim 5 , wherein the difference in UV absorption is from about 15% to about 90%.
7. The pharmaceutical package of claim 5 , wherein the difference in UV absorption is from about 50% to about 75%.